Q-omics provides the consensus-scored MIR378G profile across patient tissues and cancer cell-line models. MIR378G expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MIR378G is differentially expressed in 5, with the highest sampling consensus in STAD. Additionally, MIR378G RNA expression shows 11,344 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight MESO, STAD, and ESCA as cancer lineages where MIR378G shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR378G — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR378G survival associations across molecular data types. MIR378G RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR378G RNA expression–survival associations across cancer types. High MIR378G expression shows unfavorable associations in MESO, KIRC, ACC and LGG, but favorable associations in OV and BLCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for MIR378G RNA expression.
This table summarizes MIR378G tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for MIR378G. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR378G shows higher tumor expression in STAD, KICH, BRCA, LUAD and LUSC. The STAD box plot shows higher MIR378G RNA expression in tumor versus normal tissue (log2 FC = +0.624, t-test p = .009).
This table shows molecular features associated with MIR378G in patient tissues and cancer cell lines. In patient samples, MIR378G shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
